Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28372028 | 0.86 | CA12 (0.46) | CA12CA1CA2CA3CA4 | |
| SCHEMBL28372029 | 0.86 | CA12 (0.46) | CA12CA1CA2CA3CA4 | |
| SCHEMBL15423894 | 0.84 | CA12 (0.51) | CA12CA1CA2CA3CA4 | |
| SCHEMBL11407688 | 0.83 | CA12 (0.41) | CA12CA1CA2CA3CA4 | |
| SCHEMBL526519 | 0.83 | MAPT (0.57) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1694958 | 0.83 | MAPT (0.57) | CA12CA1CA2CA3CA4 | |
| SCHEMBL993144 | 0.83 | MAPT (0.57) | CA12CA1CA2CA3CA4 | |
| SCHEMBL16511498 | 0.83 | BIRC2 (0.38) | CA12CA1CA2CA3CA4 | |
| SCHEMBL12064041 | 0.82 | SMN1; SMN2 (0.45) | CA12CA1CA2CA3CA4 | |
| SCHEMBL12064029 | 0.82 | SMN1; SMN2 (0.45) | CA12CA1CA2CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969620-B2 | Process for the preparation of amino acid derivatives | UCB PHARMA GMBH (DE) | 2015-03-03 | — | — | US | claimed |
| US-8969620-B2 | Process for the preparation of amino acid derivatives | UCB PHARMA GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969620-B2 | Process for the preparation of amino acid derivatives | UCB PHARMA GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8957252-B2 | Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives | INDOCO REMEDIES LIMITED (IN) | 2015-02-17 | — | — | US | disclosed |
| US-8957252-B2 | Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives | INDOCO REMEDIES LIMITED (IN) | 2015-02-17 | — | — | US | disclosed |
| EP-2598476-B1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LTD (IN) | 2014-07-02 | — | — | EP | disclosed |
| EP-2598476-B1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LTD (IN) | 2014-07-02 | — | — | EP | disclosed |
| US-8759582-B2 | Process for the preparation of lacosamide | NATCO PHARMA LIMITED (IN) | 2014-06-24 | — | — | US | disclosed |
| US-8759582-B2 | Process for the preparation of lacosamide | NATCO PHARMA LIMITED (IN) | 2014-06-24 | — | — | US | disclosed |
| US-20130190533-A1 | PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | UCB PHARMA GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| EP-2598476-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | Indoco Remedies Limited (IN) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2013-05-16 | — | — | US | disclosed |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2013-05-16 | — | — | US | disclosed |
| US-20130035508-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | NATCO PHARMA LIMITED (IN) | 2013-02-07 | — | — | US | disclosed |
| US-20130035508-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | NATCO PHARMA LIMITED (IN) | 2013-02-07 | — | — | US | disclosed |
| WO-2012041986-A1 | PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | UCB PHARMA GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012014226-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011095995-A1 | A PROCESS FOR THE PREPARATION OF LACOSAMIDE | NATCO PHARMA LIMITED (IN) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035508-A1 | PROCESS FOR THE PREPARATION OF LACOSAMIDE | CA3, CACNA1A, CA2 | CA12 22/4885CA1 6/4885CA2 3/4885 |
| US-20130190533-A1 | PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | BCAT2, BCAT1, HNMT | CA12 224/4885CA1 15/4885CA2 148/4885 |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | LPXN, CACNA1B, PMP22 | CA12 138/4885CA1 78/4885CA2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.